---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342371"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2026-08-10T20:09:40+00:00"
generated_at: "2026-08-10T20:11:40.730515+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sana Biotech Q2 2026: Net loss narrows to $63.6M; cash $160.5M, runway into mid-2027

## Summary
- Q2 net loss $63.6M ($0.22/sh) vs $93.8M ($0.39) year ago; non-GAAP loss $39.7M ($0.13).
- Cash, equivalents, marketable securities $160.5M at 6/30/26; raised $93.3M from ATM and Mayo Clinic's $25M equity investment.
- SC451 IND and Phase 1/2 start expected as early as this year; SG293 first-in-human data expected as early as this year.
- UP421 14-month data published in NEJM: C-peptide present, no immunosuppression, no safety issues.
- Mayo Clinic collaboration to accelerate SC451 development; $25M equity investment.

## SEC filing metadata
- accession: 0001193125-26-342371
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2026-08-10T20:09:40+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000119312526342371/0001193125-26-342371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000119312526342371/sana-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342371
- JSON: https://secwatch.observer/filing/0001193125-26-342371.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342371.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.